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CI NRM CI REL RFS OS
No AZA
1yr 18.7 (10.5 e 28.7) 38.6 (27.6 e 50.2) 42.9 (31.6 e 54.5) 58.6 (46.9 e 69.8)
3yrs 35.7 (24.7 e 47.4) 41.4 (30.2 e 53.1) 24.1 (14.8 e 34.8) 28.3 (18.4 e 39.4)
Yes AZA
1yr 18.1 (10.8 e 26.8) 27.0 (18.3 e 36.6) 55.1 (44.7 e 65.2) 67.4 (57.4 e 76.7)
3yrs 24.1 (15.7 e 33.5) 33.9 (24.4 e 44.0) 42.5 (32.5 e 52.9) 48.0 (37.7 e 58.4)
P¼0.05 P¼0.06
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S222Utilization of pre-HCT 5-aza is a feasible strategy and doesn’t
appear to have any negative impact on HCT outcomes. Given
the beneﬁcial disease control facilitated by aza it should be
offered to patients with high risk MDS being considered for
a HCT.342
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Background: In spite of modern antimicrobial and sup-
portive therapy, bacterial and fungal infections are still major
complications in patients with profound neutropenia. For
decades, the value of granulocyte transfusion (GTX) has been
explored and results are still not conclusive. Neutropenia
caused by transplant conditioning regimens in patients who
fail to respond to antimicrobial agents is one of the most
common indications for GTX.
Objective: The purpose of this study was to analyze out-
comes and risk factors for survival in patients who received
GTX.
Patients and Methods: a retrospective analysis was per-
formed on all patients submitted allogeneic hematopoietic
cell transplantation (HSCT) who received GTX from january
2006 to april 2013 in our center. We analyzed patients
characteristics, survival and identiﬁed risk factors for sur-
vival. Statistical analyses were performed using Graphpad
Prism version 6.0. Fisher exact test was used to compare
categoric variables and Kaplan-Meyer to evaluate survival.
P level signiﬁcance was < 0,05.
Results: We investigate the efﬁcacy of GTX into 32 patients
with severe neutropenia and fungal and/or bacterial in-
fections. There were 50% (n¼ 16) females and 50% (n¼ 16)
males. Of these, 46,8% (n¼ 15) were adults. Twenty-ﬁve
percent of patients (n¼ 8) had genetic diseases, 43,8% (n¼
14) had severe aplastic anemia and 31,2% (n¼ 10) had other
malignant hematological diseases. A total of 196 GTX were
perfomed. The average number of transfusion by patient was
6,125. The average number of granulocyte count in each bag
was 3,84x1010. Every patients had neutrophil count at the
hemogram below 100/mm3 and had unresponsive severe
infection to antimicrobial and antifungal treatment at the
day of the ﬁrst GTX. In the period of infection, 56,3% (n¼ 18)
had bacteria identiﬁed by culture: 61,1% (n¼ 11) gram-posi-
tive and 38,8% (n¼ 7) gram-negative; and 65,6% hadpresumed or conﬁrmed fungal infection: 33,4% (n¼ 7)
Fusarium sp, 38,1% (n¼ 8) Aspergillus sp, 9,5% (n¼ 2) Candida
sp, 19% (n¼ 4) probable invasive fungal disease). Five patients
received only one GTX before dying. Median survival for the
whole cohort was 103 days. There was no signiﬁcant differ-
ence in survival according to age, disease, number of GTX
received and donor source. In bivariate analysis, patients
with age higher than 14 years old and patients who received
less than ﬁve transfusions had higher chance of death
(p¼0,015, OR-7,3 and p¼0,03, OR-3,61 respectively).
Conclusion: GTX may have an adjunctive role in severe in-
fections in patients with profound neutropenia submitted to
HSCT. Children and more than ﬁve GTX were protective
factors. GTX is an underutilized supportive modality for
critically ill patients undergoing allogeneic HSCT and it
seems to bring beneﬁts in some groups of patients. Pro-
spective randomized studies are necessary to a better eval-
uation of this procedure.343
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Cytomegalovirus (CMV) infection is a major cause of
morbidity and mortality following allogeneic stem cell
transplantation (SCT). We wanted to study the incidence of
CMV reactivation following SCT is high in a populationwhere
previous exposure to CMV is high. This is a retrospective
analysis of consecutive transplants done in the Department
of Haematology, Christian Medical College, Vellore India
between January 2008 and December 2012. Recipient and
donor demographics along with transplant data were
recorded. Patients were monitored for CMV reactivation
weekly using a CMV DNA PCR in the ﬁrst 100 days post SCT.
Four hundred and seventy ﬁve patients with a median age of
21 years (range: 1-59) underwent SCT for both malignant
and non-malignant indications. Of these, 459 (97.2%) were
CMV IgG positive. Donors were either sibling (n ¼ 393) or
matched unrelated (n¼ 82). CMV reactivation occurred in
36.6% at a median time of 41 days post SCT (range: 10 - 100).
CMV disease occurred in 8 patients (1.68%). The use of a male
donor (p¼0.000), unrelated donor (p¼0.000), degree of HLA
mismatch (p¼0.000), neutrophil recovery <15 days
(p¼0.005), acute GVHD (p¼0.000) and steroid refractory
GVHD (p¼0.028) were identiﬁed as risk factors for CMV
reactivation on univariate analysis. On multivariate analysis
degree of HLA mismatch (p¼0.009), early neutrophil recov-
ery (p¼0.014) and steroid refractory GVHD (p¼0.014)
remained independent risk factors. Most of the patients were
treated with ganciclovir for a median duration of 16 days (14
e 21). The 5 year overall survival was signiﬁcantly lower in
